Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01302795
Other study ID # DER-USZ-AAN-008
Secondary ID
Status Completed
Phase Phase 2
First received February 17, 2011
Last updated September 26, 2016
Start date February 2011
Est. completion date November 2015

Study information

Verified date September 2016
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.


Description:

At the start of the study (week 0), all patients will receive one subcutaneous injection of 150mg Canakinumab. Patients are then going to be examined at weeks 2, 4, 8, 12 and 16.

At 2 weeks, all patients are going to be evaluated for response by Physician's global assessment (PGA) of the target lesion. Patients with PGA 0-1 are not going to receive another injection at this timepoint, while patients with PGA 2-4 are going to receive another 150mg Canakinumab.

At 4 weeks, in case of PGA 4, patients are going to be offered a first or second line drug as an alternative therapy (corticosteroids, cyclosporin A or infliximab, dosage see below "Alternative therapy in case of missing response") and stay within the trial (due to the long half-life of canakinumab) until week 8.

At week 8, patients with PGA 0 receive another 150mg Canakinumab only, and patients with PGA 4 are not going to receive additional study drug, but are strongly encouraged to attend following medical visits for observation until the end of the study and/or switch to a first or second line drug as alternative therapy (see below). All other patients with PGA 1-3 receive the total accumulative dose of Canakinumab that they had received on week 0 and 2, namely 150 or 300mg.

The study duration for each individual is going to be 16 weeks. At week 8 and 16, safety laboratory investigations with blood differential (Neutrophil granulocytes, monocytes, eosinophils, basophils, lymphocytes, thrombocytes, erythrocytes, hemoglobin), AST, ALT, y-GT, AP, Bilirubin (total), Creatinine, Na, K, CRP are going to be determined.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date November 2015
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 99 Years
Eligibility Inclusion criteria: Patients fulfilling all of the following inclusion criteria may be enrolled in the study

1. Age = 18 years of age at visit 0 and

2. Subjects are capable of giving informed consent

3. Non-healing ulcer with primarily neutrophil infiltration, regardless of size and location

4. Diagnosis of pyoderma gangrenosum as confirmed by clinical and histological examination (see exclusion criteria). In case of doubt, a steering committee consisting of experts of the participating centers is going to evaluate whether inclusion is possible or not

Exclusion criteria:

- Other etiologies of ulcers 15, namely venous insufficiency, arterial occlusion, microcirculatory disorders, physical or chemical injury, infection, neuropathy, vasculitis, haematological disorders, neoplasia, other ulcerating diseases: Diseases with cutaneous manifestations mimicking pyoderma gangrenosum, including but not limited to Wegener's granulomatosis, polyarteritis nodosa, lymphoma, sporotrichosis and antiphospholipid syndrome.

- Classical systemic therapy (including but not limited to: corticosteroids, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, dapsone, cyclophosphamide) affecting pyoderma gangrenosum less than 14 days prior to enrollment.

- Therapy with other biologics (TNF antagonists, intravenous immunoglobulins) less than 3 months or 5 half-lives prior to enrollment, whichever is longer.

- Any other investigational drugs, other than investigational biologic treatment, within 30 days (or 3 months for investigational monoclonal antibodies) or 5 half-lives prior to the baseline visit, whichever is longer. Washout period may be longer according to local requirements.

- Topical therapy affecting pyoderma gangrenosum for a period of 14 days prior to enrollment.

- Having a history of recurring bacterial, viral, fungal, atypical mycobacterial infection, especially active or latent granulomatous infections (incl. tuberculosis, histoplasmosis) or currently undergoing treatment for tuberculosis.

- A positive quantiferon test indicating possible latent tuberculosis infection.

- An abnormal chest x-ray indicating a possible infection or malignoma for a period of 3 months prior to enrollment.

- Known Human Immunodeficiency Virus (HIV)-, Hepatitis B (HBV)-, or Hepatitis C (HCV)-infection.

- Having a severe medical condition that, in the judgment of the investigator, would jeopardize in any way the subject's safety following exposure to study drug.

- Pregnant or lactating women, patients (men or women) planning a pregnancy during the duration of the study, lack of safe contraception.

Safe contraception is defined as follows:

Double-barrier contraception such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices together with condom use.

Both men and women must use safe contraception (double-barrier as defined above) during the duration of the study and until 6 months after the study.

Please note that female subjects who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.

- Having the presence or history of malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled.

- Contraindications to monoclonal or polyclonal antibodies, e.g. known hypersensitivity or allergy to class of drugs or the investigational product.

- Known or suspected non-compliance, drug or alcohol abuse.

- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia or confusional state of the subject.

- Participation in another treatment study within the 30 days preceding and during the present study.

- Previous enrollment into the current study.

- Enrollment of the investigator, his/her family members, employees and other dependent persons.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Canakinumab
Monoclonal antibody inhibiting interleukin 1 beta

Locations

Country Name City State
Switzerland Department of Dermatology, University Hospital Zurich Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the Physician's global assessment (Grade 0-4) of the target lesion The primary response parameter change of the physician global assessment (PGA) 5-point scale at week 2, 4, 8, 16 as compared to week 0 :
0= Total resolution of target ulcer with no signs of active PG
Almost completely healed target ulcer with only minimal signs of active PG
Evidence of target ulcer healing which involves at least 50% of ulcer/ulcer margin
Evidence of target ulcer healing which involves less than 50% of ulcer/ulcer margin
No evidence of target healing ulcer
Week 2, 4, 8, 16 No
Secondary Change in surface area of the target lesion of pyoderma gangrenosum As secondary parameter, the change in surface area of the target lesion of pyoderma gangrenosum at week 2, 4, 8, 16 as compared to week 0 will be assessed by measuring the two-dimensional surface by tracing the border of the lesions on transparent foil as well as with Canfield photography. Week 2, 4, 8, 16 No
Secondary Change in surface area of the non-target lesions As secondary parameter, the change in surface area of the non-target lesions of pyoderma gangrenosum at week 2, 4, 8, 16 as compared to week 0 will be assessed by measuring the two-dimensional surface by tracing the border of the lesions on transparent foil as well as with Canfield photography. Week 2, 4, 8, 16 No
See also
  Status Clinical Trial Phase
Recruiting NCT06092216 - Spesolimab in Pyoderma Gangrenosum Phase 2
Completed NCT03311464 - A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Phase 3
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Completed NCT00791557 - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease N/A
Terminated NCT02318914 - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Phase 3
Terminated NCT02315417 - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Phase 3
Completed NCT03137160 - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT05984654 - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum N/A
Completed NCT04895566 - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Early Phase 1
Withdrawn NCT04274166 - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Phase 2
Completed NCT01882504 - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Withdrawn NCT00730717 - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT03971643 - Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT04792957 - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting NCT05821374 - Deucravacitinib in PG Early Phase 1
Terminated NCT03072953 - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Phase 2
Recruiting NCT05120726 - A Novel Therapeutic Treatment of Pyoderma Gangrenosum Phase 4
Withdrawn NCT00690846 - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT01965613 - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Phase 2
Recruiting NCT01952275 - Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases N/A